Global Opioid Induced Constipation Treatment Market Overview
Opioids are medications that block pain signals by attaching throughout the nervous system to the receptor cells which are also found in the bowels. Application of opioids results in distention and bulged abdomen with dry and hard stools. Thus, these medications increase the overall time of stool passage through the system by attaching to the receptors in the gut. Opioids are used for reducing non-cancerous chronic pains which generally result in constipation which is defined as less than three bowel movements in a week. The constipation induced by opioids can be treated with the help of stimulants, stool softeners, and osmotics. Stimulants increase intestinal contractions and induce bowel activity whereas stool softeners helps in easier stool passage by increasing the water content in the colon and osmotics aid in constipation treatment by helping movement of fluid through the colon. There are various laxatives present in the market for the purpose of stool softening as an Over the Counter (OTC) option in rectal and oral formulations. Opioid induced constipation can also be treated by various prescription drugs such as, naloxegol, methylnaltrexone and others that are present easily in the market.
Market Size & Forecast
Opioid induced constipation treatment market is anticipated to record a CAGR of 4.3% over the forecast period. Currently the global opioid induced constipation treatment market is observing vibrant growth on account of increasing demand of constipation treatment in the market. Advances in pharmaceutical industry in the past few years and growing technological explorations are projected to drive opioid induced constipation treatment market during the forecast period. Many multi-national companies are concentrating towards new product advances in opioid induced constipation treatment. New medicines for opioid induced constipation treatment are being discovered on regular basis due to increased incidences of opioid induced constipation by increasing use of pain killers which is expected to drive the opioid induced constipation treatment market rapidly.
On the basis of regional platform, global Opioid Induced Constipation Treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.
Europe is expected to drive demand and positively impact the opioid induced constipation treatment market growth over the forecast period on account of increasing opioid induced constipation treatment application for stool softening and easy bowel movement processes. With rising number of opioid addicts across the region, North America is panned to observe substantial growth in opioid induced constipation treatment market on the back of rising opioid induced constipation treatment requirement in the addiction population. North America is expected to be followed by Asia Pacific in terms of consumption due to expanding opioid induced constipation treatment requirements in opioids used for treating diarrhea patients and surgically treated patients. On the back of multiplying opioid induced constipation treatment uses in growing end-users, Asia Pacific is budding as a regional opioid induced constipation treatment consumption market.
Growth Drivers & Challenges
Increasingly Busy Work Schedules resulting in Increased Opioid Intake
The rising demand for opioid induced constipation treatment for various processes such as bowel movement regulation, colon clearing and stool softening in healthcare industry is expected to drive the market rapidly over the forecast period. The growing R&D activity associated to opioid induced constipation treatment is further expected to increase the market growth on the back of discovery of new drugs on regular basis. Rise in number of spinal pains and headaches on account of busy work schedules in men and women have propelled the use of opioids for reducing pain which is estimated to drive the opioid induced constipation treatment market as well.
Lack of Awareness
However, cost constraints associated to adoption of novel drugs and pharmaceuticals along with lack of awareness regarding forthcoming innovative treatments as well as regulatory bodies unfavorable reimbursement guidelines are expected to serve as various restraints in the growth of the opioid induced constipation treatment market over the forecast period.
Increasing Opioid Addiction and Healthcare Expenditure
Conversely, increasing opioid addiction and base of illegal medications users is anticipated to contribute significantly in the growth of opioid induced constipation treatment market. Additionally, increasing urbanization with growing healthcare expenditure of individuals and transfers from government domestic revenue for healthcare such as, 72.2% by Canada Gov., 42.3% by Japanese Gov., 80.1% by U.K Gov. and many others as per the reports of OECD, is expected to propel the opioid induced constipation treatment market over the forecast period. Moreover, undiscovered market for advantageous, safe and successful treatment medication has been assessed to be profoundly broad and developing in over the counter drugs. Furthermore, increasing number of population undergoing surgical procedures has induced an increased use of pain killers leading in rise in number of patients suffering from opioid induced constipation which is directly anticipated to impact the opioid induced constipation treatment market positively across the globe.
Our-in depth analysis of the global Opioid Induced Constipation Treatment market includes the following segments:
By Drug Classes
By Distribution Channel
Global Opioid Induced Constipation Treatment Market is further classified on the basis of region as follows:
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization
Great focus on accuracy and quality of the research
(U.S.) - +1 646 586 9123
(Canada) - +1 437 889 3230
(U.K.) - +44 203 608 5919
(India) - + 91 120 660 5495